A vaccine for pancreatic cancer can serve as a promising new therapy.
At the Memorial Slone Catering Cancer Center (MSK) in New York, an envoy RNA (MRNA)-An experimental approach to treat cancer with based medical vaccine “continues to reduce the risk of disease after surgery”, of surgery Later a press release in reducing the risk of the disease.
The results of phase 1 clinical test published in Journal Nature showed that the vaccine triggered an immune response in a small patient group.
Cancer vaccine shows promising results for some patients
This immune-cell activation persisted for about four years after treatment, it is said in the release.
Patients who received the vaccine and showed an immune system response were more likely to live cancer -free by a three -year follow -up.
Step 1 continues to show the results from the clinical trial, “MSK stated in a press release. (Istock)
The head investigator of the test and senior study writer, MD, Vinod Balachandran at MSK said his optimism about the efficacy of this treatment.
“We find that with the RNA vaccine technique, we can teach the immune system to identify pancreatic cancer, and this immune response may last for many years,” he said.
“The ability to trigger a strong, long lasting immune response is an expected feature for any cancer vaccines.”
Cases of prostate cancer share the potential reasons as spikes in this US state
As it is difficult to treat pancreatic cancer, “Balachandran shared his surprise that the immune system responded in some patients.
“We are encouraged to see that our approach can teach the immune system to recognize pancreatic cancer, that the immune response is powerful and it can potentially affect patients,” he said.
“The ability to trigger a strong, long lasting immune response is an expected feature for any cancer vaccines.”
“Although the conclusions are promising, these vaccines are still in the early stages of the test,” Balachandran said.
The team is planning a major study, “to test these medical cancer vaccines in cancer patients with surgical pancreatic pancreatic cancer.”
Therapeutic vaccines target the early stages of cancer, where the tumor can be removed from the surgery and not spread. (Istock)
Of the 16 participants, the vaccine inspired one immune response in half of them. The cancer vaccine was individual for each participant to target specific proteins found as a disease individually disease.
After receiving the surgery, patients also received an immunotherapy drug (atezolizumab) and standard-care chemotherapy.
Click here to get Fox News app
According to the researchers, such medical cancer vaccines, such the identical cancer vaccines, which are referred to as autogen kevumeran, instead of preventing it, the immune system to treat cancer instead of preventing it “Cancer cells” It is done to recognize “as a foreigner.
Patients who had an immune response to vaccines were more likely to reduce the risk of cancer by a three-year check-up. (Istock)
The vaccine is meant to target the early stages of cancer that have not spread, where the tumor can be removed from the surgery, “to help prevent delay or recurrence.”
Balachandran said that this approach can potentially be applied to other forms of cancer.
“If you can do this in pancreatic cancer, theoretically you may be able to develop medical vaccines for other cancer types.”
“For patients with pancreatic cancer, our latest results continue to support the approach to using individual MRNA vaccines to target new castes in each patient’s tumors,” he said.
“If you can do this in pancreatic cancer, theoretically you may be able to develop medical vaccines for other cancer types.”
For more health articles, travel www.foxnews.com/health
According to MSK and American Cancer Society, pancreatic cancer is one of the most deadly cancer, as only 13% of patients are alive after five years of diagnosis.
Click here to sign up for our health newspaper
General treatments such as chemotherapy, radiation and immunotherapy are “largely ineffective” against pancreatic cancer, said MSK, which is “immediate need for new remedies.”
